Features of Streptococcus agalactiae strains recovered from pregnant women and newborns attending different hospitals in Ethiopia.
Anti-Bacterial Agents
/ pharmacology
Cross-Sectional Studies
Drug Resistance, Bacterial
/ drug effects
Ethiopia
/ epidemiology
Female
Genotype
Humans
Infant, Newborn
Microbial Sensitivity Tests
Multilocus Sequence Typing
Pregnancy
Pregnancy Complications, Infectious
/ diagnosis
Prospective Studies
Sepsis
/ diagnosis
Serogroup
Streptococcal Infections
/ diagnosis
Streptococcus agalactiae
/ genetics
Whole Genome Sequencing
Antibiotic resistance
GBS
S. agalactiae
Sequence type
Serotype
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
16 Nov 2020
16 Nov 2020
Historique:
received:
25
06
2020
accepted:
03
11
2020
entrez:
17
11
2020
pubmed:
18
11
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Streptococcus agalactiae (Group B Streptococcus, GBS) serotypes, sequence types, and antimicrobial resistance profile vary across different geographic locations affecting disease patterns in newborns. These differences are important considerations for vaccine development efforts and data from large countries in Africa is limited. The aim of this study was to determine serotypes and genotypes of GBS isolates from pregnant women and their newborns in Ethiopia. A hospital based cross-sectional study was conducted at three hospitals in Ethiopia from June 2014 to September 2015. Out of 225 GBS isolates, 121 GBS were recovered, confirmed and characterized at CDC's Streptococcus Laboratory using conventional microbiology methods and whole genome sequencing. Of the 121 isolates, 87 were from rectovaginal samples of pregnant women, 32 from different body parts of their newborns and 2 from blood of newborns with suspected sepsis. There were 25 mother-infant pairs and 24 pairs had concordant strains. The most prevalent serotypes among mothers and/or their babies were II, Ia and V (41.5, 20.6, 19.5 and 40.6%, 25 and 15.6%, respectively). Multilocus sequence typing (MLST) on 83 isolates showed ST10 (24; 28.9%) and ST2 (12; 14.5%) as most predominant sequence types. All GBS strains were susceptible to penicillin, cefotaxime and vancomycin, which correlated to the presence of wildtype PBP2x types and the lack of known vancomycin-resistance genes. Tetracycline resistance was high (73; 88%, associated primarily with tetM, but also tetO and tetL). Five isolates (6%) were resistant to erythromycin and clindamycin and 3 isolates were fluoroquinolone-resistant, containing associated mutations in gyrA and parC genes. All isolates were positive for one of four homologous Alpha/Rib family determinants and 1-2 of the three main pilus types. Predominant serotypes were II, Ia, and V. A limited number of clonal types were identified with two STs accounting for about half of the isolates. All strains collected in this study were susceptible to beta-lactam antibiotics and vancomycin. Typical of most GBS, these isolates were positive for single alpha-like family protein, serine-rich repeat gene, as well as 1-2 pilus determinants.
Sections du résumé
BACKGROUND
BACKGROUND
Streptococcus agalactiae (Group B Streptococcus, GBS) serotypes, sequence types, and antimicrobial resistance profile vary across different geographic locations affecting disease patterns in newborns. These differences are important considerations for vaccine development efforts and data from large countries in Africa is limited. The aim of this study was to determine serotypes and genotypes of GBS isolates from pregnant women and their newborns in Ethiopia.
METHODS
METHODS
A hospital based cross-sectional study was conducted at three hospitals in Ethiopia from June 2014 to September 2015. Out of 225 GBS isolates, 121 GBS were recovered, confirmed and characterized at CDC's Streptococcus Laboratory using conventional microbiology methods and whole genome sequencing.
RESULTS
RESULTS
Of the 121 isolates, 87 were from rectovaginal samples of pregnant women, 32 from different body parts of their newborns and 2 from blood of newborns with suspected sepsis. There were 25 mother-infant pairs and 24 pairs had concordant strains. The most prevalent serotypes among mothers and/or their babies were II, Ia and V (41.5, 20.6, 19.5 and 40.6%, 25 and 15.6%, respectively). Multilocus sequence typing (MLST) on 83 isolates showed ST10 (24; 28.9%) and ST2 (12; 14.5%) as most predominant sequence types. All GBS strains were susceptible to penicillin, cefotaxime and vancomycin, which correlated to the presence of wildtype PBP2x types and the lack of known vancomycin-resistance genes. Tetracycline resistance was high (73; 88%, associated primarily with tetM, but also tetO and tetL). Five isolates (6%) were resistant to erythromycin and clindamycin and 3 isolates were fluoroquinolone-resistant, containing associated mutations in gyrA and parC genes. All isolates were positive for one of four homologous Alpha/Rib family determinants and 1-2 of the three main pilus types.
CONCLUSIONS
CONCLUSIONS
Predominant serotypes were II, Ia, and V. A limited number of clonal types were identified with two STs accounting for about half of the isolates. All strains collected in this study were susceptible to beta-lactam antibiotics and vancomycin. Typical of most GBS, these isolates were positive for single alpha-like family protein, serine-rich repeat gene, as well as 1-2 pilus determinants.
Identifiants
pubmed: 33198686
doi: 10.1186/s12879-020-05581-8
pii: 10.1186/s12879-020-05581-8
pmc: PMC7668015
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
848Références
Can J Infect Dis Med Microbiol. 2016;2016:6403928
pubmed: 27559344
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S125-S132
pubmed: 29117322
Lancet Infect Dis. 2016 May;16(5):546-555
pubmed: 26869376
J Clin Microbiol. 2003 Jun;41(6):2530-6
pubmed: 12791877
Vaccine. 2016 Jun 3;34(26):2876-2879
pubmed: 26988258
Microbiol Spectr. 2019 Mar;7(2):
pubmed: 30873933
J Microbiol Methods. 2010 Feb;80(2):212-4
pubmed: 19958797
Obstet Gynecol. 2014 Apr;123(4):828-37
pubmed: 24785612
BMC Res Notes. 2016 Jul 19;9:351
pubmed: 27435469
Antimicrob Agents Chemother. 2015 Apr;59(4):2466-9
pubmed: 25666148
J Antimicrob Chemother. 2015;70(6):1601-3
pubmed: 25667406
J Clin Microbiol. 2007 Sep;45(9):2929-36
pubmed: 17634306
Microbes Infect. 2006 Jun;8(7):1714-22
pubmed: 16822689
J Infect Dis. 2009 Jan 1;199(1):108-15
pubmed: 19086816
Pediatr Infect Dis J. 2016 Sep;35(9):933-42
pubmed: 27213263
J Exp Med. 2010 Oct 25;207(11):2313-22
pubmed: 20956545
Ann Clin Microbiol Antimicrob. 2019 Jan 19;18(1):3
pubmed: 30660188
Nat Commun. 2014 Aug 04;5:4544
pubmed: 25088811
J Bacteriol. 2004 Mar;186(5):1518-30
pubmed: 14973027
J Infect Dis. 2012 Dec 1;206(11):1745-52
pubmed: 23002446
Cell Host Microbe. 2007 Dec 13;2(6):427-34
pubmed: 18078694
Emerg Infect Dis. 2015 Apr;21(4):585-91
pubmed: 25811284
Pediatr Infect Dis J. 2003 Feb;22(2):e1-11
pubmed: 12586987
Indian J Med Res. 2004 May;119 Suppl:205-7
pubmed: 15232196
Mem Inst Oswaldo Cruz. 2011 Mar;106(2):119-22
pubmed: 21537668
BMC Res Notes. 2015 Aug 20;8:364
pubmed: 26289147
Antimicrob Agents Chemother. 2008 May;52(5):1888-90
pubmed: 18299411
Med Princ Pract. 2014;23(4):323-30
pubmed: 24820221
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S100-S111
pubmed: 29117327
BMC Pregnancy Childbirth. 2018 May 4;18(1):135
pubmed: 29728084
BMC Infect Dis. 2020 Jan 13;20(1):35
pubmed: 31931732
Ann Lab Med. 2019 Jul;39(4):414-416
pubmed: 30809991
Ann Clin Microbiol Antimicrob. 2019 Mar 28;18(1):14
pubmed: 30922308
J Antimicrob Chemother. 2017 Jul 1;72(7):1886-1892
pubmed: 28333320
Clin Microbiol Infect. 2017 Aug;23(8):574.e7-574.e14
pubmed: 28257899
Clin Infect Dis. 2020 Feb 15;:
pubmed: 32060499
PLoS One. 2017 Aug 15;12(8):e0183083
pubmed: 28813477